With 7.15 million shares changed hands, the volume of the stock remained lighter than its average volume of 10.27 million shares. The 52-week range on HIVE shows that it touched its highest point at $5.54 and its lowest point at $1.69 during that stretch. It currently has a 1-year price target of $8.06. Beta for the stock currently stands at 4.77.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HIVE was down-trending over the past week, with a drop of -7.37%, but this was down by -37.81% over a month. Three-month performance dropped to -57.07% while six-month performance fell -31.78%. The stock lost -48.08% in the past year, while it has lost -38.25% so far this year. A look at the trailing 12-month EPS for HIVE yields -0.06 with Next year EPS estimates of 0.05. For the next quarter, that number is -0.09. This implies an EPS growth rate of 72.98% for this year and 134.98% for next year.
Float and Shares Shorts:
At present, 155.40 million HIVE shares are outstanding with a float of 154.63 million shares on hand for trading.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HIVE since 3 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.52827 being high and -$0.79885 being low. For HIVE, this leads to a yearly average estimate of -$0.67. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
